STOCKWATCH
·
Pharmaceuticals
Quarterly Result5 Feb 2026, 06:15 pm

FDC Limited Announces Q3 FY26 Results: Revenue Growth of 0.1%, EBITDA Margin at 11.2%

AI Summary

FDC Limited, a leading manufacturer and exporter of foods, drugs, and chemicals, has announced its financial results for the third quarter and nine months ended December 31, 2025. The company reported a marginal growth of 0.1% in Q3 FY26 revenue from operations, primarily due to lower sales in the Domestic Formulations business. However, the Export Formulations business delivered a strong growth of 55.0% Y-o-Y. The API business declined by 17.0% Y-o-Y. The US business continued its recovery, with a 2.1% Y-o-Y growth in overall revenue. The company's EBITDA for Q3 FY26 stood at Rs. 52 crores, with margins at 11.2%.

Key Highlights

  • Revenue from operations stood at Rs. 465 crores, registering a marginal growth of 0.1% Y-o-Y
  • Export Formulations business delivered strong growth of 55.0% Y-o-Y
  • API business declined by 17.0% Y-o-Y
  • US business continued its recovery with a 2.1% Y-o-Y growth
  • EBITDA for Q3 FY26 stood at Rs. 52 crores, with margins at 11.2%
FDC
Pharmaceuticals
FDC LTD.

Price Impact